A chair for particular use in clinical or hospital environments has a frame to which a support material is secured. The support material may form a chair back and/or a seat for the chair to provide support to the chair occupant. The support material may be made from a textile of interwoven strands wherein some of the interwoven strands include copper containing particles, such as copper iodide or copper oxide within the textile fibers.
|
1. A chair comprising:
(A) a seat frame; and
(B) a support material that is supported by the seat frame and that provides a support for an occupant of the chair; wherein the support material comprises a mesh having a plurality of interwoven strands, wherein the plurality of interwoven strands comprise one or more interwoven strands that include a copper infusion.
8. A chair comprising:
(A) a seat frame; and
(B) a support material that is supported by the seat frame and that provides a support for an occupant of the chair; wherein the support material comprises a mesh having a plurality of interwoven strands, wherein the plurality of interwoven strands comprise copper containing particles within the plurality of interwoven strands.
3. The chair of
7. The chair of
10. The chair of
14. The chair of
|
This application is a continuation-in-part of U.S. patent application Ser. No. 17/204,751 filed on 17 Mar. 2021, now U.S. Pat. No. 11,389,009 which is a continuation of U.S. patent application Ser. No. 15/855,762 filed 27 Dec. 2017, now U.S. Pat. No. 10,986,938, which claims priority to U.S. provisional patent application Ser. No. 62/439,299, filed 27 Dec. 2016, the contents of which are herein incorporated by reference.
The present invention relates to chairs and in particular to chairs used in clinical environments and the like where the surfaces of the chair may be exposed to unsanitary conditions.
Clinical areas, hospitals, health centers and the like, require the use of cleaners to reduce the amount of bacteria and other microbes that collect on surfaces. Because of this, fabrics used on furniture, such as chairs, generally need to be sturdy and sufficiently robust to withstand multiple harsh cleaning cycles. Unfortunately, suitable fabrics such as vinyl, hard plastics, etc. tend to be less breathable and therefore less comfortable.
What is required is an improved fabric for use in chairs and similar furniture that can withstand the harsh clinical environment.
The various embodiments of the present invention may, but do not necessarily, achieve one or more of the following advantages:
provide a chair with improved cleanable surfaces;
provide a chair for use in clinical environments that can withstand harsh cleaning; and
provide a chair for use in clinical environments that has a breathable fabric.
These and other advantages may be realized by reference to the remaining portions of the specification, claims, and abstract.
In one aspect, there is provided a chair. The chair may have a seat frame that supports a fabric. The fabric provides a support for an occupant of the chair. The fabric may comprise a mesh. The mesh may be comprised of strands, fibers, threads etc. The strands may include one or more strands that include a copper infusion.
In one aspect, there is provided a chair. The chair may have a seat frame that supports a fabric. The fabric provides a support for an occupant of the chair. The fabric may comprise a mesh. The mesh may be comprised of strands, fibers, threads etc. The strands may include copper containing particles within the strands.
In one aspect, there is provided a chair for particular use in clinical or hospital environments. The chair has a frame to which a support material is secured. The support material may form a chair back and/or a seat for the chair to provide support to the chair occupant. The support material may be made from a textile that includes copper containing particles such as copper iodide or copper oxide within the textile fibers.
The above description sets forth, rather broadly, a summary of one embodiment of the present invention so that the detailed description that follows may be better understood and contributions of the present invention to the art may be better appreciated. Some of the embodiments of the present invention may not include all of the features or characteristics listed in the above summary. There are, of course, additional features of the invention that will be described below and will form the subject matter of claims. In this respect, before explaining at least one preferred embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of the construction and to the arrangement of the components set forth in the following description. The invention is capable of other embodiments and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting.
It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.
The present invention, as described herein, includes a chair in which the support fabric is a mesh. Mesh fabrics are rarely used in clinical or hospital environments. The problem with mesh is that it is made of materials that are woven together or intertwined and stretched across the back, and, this material breaks down when cleaned with strong cleaners like bleach.
In the present application, the mesh that is typically used in a mesh chair is replaced with a mesh including copper infused strands. The strands may be, for example, a polymer, nylon or similar type material to which a copper compound such as cuprous oxide, cuprous iodide etc. is added prior to the material being drawn into fibers or strands. In one particular embodiment, the strands are drawn from a polymer in which cuprous iodide particles are dispersed. The cuprous iodide particles may have a size generally between about 0.50 and about 2.0 microns and are dispersed within the polymer to produce a resultant fiber having a percentage weight of approximately 4% cuprous iodide.
The copper infusion has been demonstrated to improve the antibacterial and/or antiviral properties of the material.
Chairs manufactured using copper infused fibers as the mesh material have been tested by the present inventors and shown to be as good or better at reducing the colony count of bacteria as other bacteria reducing fabrics. Without the copper infusion, normal mesh grows bacteria at a rate that is far higher and one that would not be acceptable for hospitals because it can't be cleaned by a high enough concentration of bleach without compromising the mesh to the point it will fail in the chair.
Thus, the mesh chairs as described herein can be used in hospitals and similar clinical environments in a way that they could not before. Many people prefer mesh to vinyl covered foam, hard plastics, etc because it is comfortable, breathable, and slim line.
The present invention comprises a chair. The chair includes a frame over which is applied a mesh fabric that includes a copper infusion as described herein. The frame may be plastic, metal, or any suitable sturdy material. In one embodiment, the mesh has weft yarns with 1200 polyester and warp yarns 2300 denier. The base material of the mesh may be polyester or polyester copolymer. The mesh material may be chosen do have a degree a elasticity and/or resilience to make it suitable and comfortable as a chair support material. The mesh material may be used as the seat support and/or as a backing support to support the occupant in the chair. The mesh may be secured to the frame using any suitable technology known in the art, including sleeves, stitching, fasteners (rivets, screws, pins, staples, etc.) and the like.
A first embodiment of a chair is shown in
A second embodiment of a chair is shown in
A third embodiment of a chair is shown in
The arm rests 64 shown as vinyl or leather armrests may be replaced by armrests having an armrest frame 74 (
In a further embodiment, the copper mesh fabric used for any portion of the chair, e.g. seat, back, armrests, may be replaced by other textiles containing a copper component for its antibacterial properties. In one embodiment, foam cushion components may be created by covering a foam cushion with a material containing a copper substance. In one embodiment, the material may be fabric produced of tightly knitted strands of the copper infused thread. In one embodiment, the material may be a vinyl produced by incorporating a copper substance into the molten resin when the vinyl is extruded. In one embodiment, the material may be a leather produced by treating the hide with a copper containing substance during the tanning process. The copper substance may be added to the pigments, dies and conditioners applied to the surface of the leather.
Although the description above contains many specifications, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the embodiments of this invention. Thus, the scope of the invention should be determined by the appended claims and their legal equivalents rather than by the examples given.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
2684709, | |||
885271, | |||
D720551, | Jun 30 2014 | SHIN CREST, PTE, LTD | Chair |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jul 15 2022 | Via. Inc. | (assignment on the face of the patent) | / | |||
Jul 08 2024 | HEPLER, JOHN CHARLES | VIA, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 067930 | /0006 |
Date | Maintenance Fee Events |
Jul 15 2022 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
Jul 26 2022 | SMAL: Entity status set to Small. |
Date | Maintenance Schedule |
Mar 05 2027 | 4 years fee payment window open |
Sep 05 2027 | 6 months grace period start (w surcharge) |
Mar 05 2028 | patent expiry (for year 4) |
Mar 05 2030 | 2 years to revive unintentionally abandoned end. (for year 4) |
Mar 05 2031 | 8 years fee payment window open |
Sep 05 2031 | 6 months grace period start (w surcharge) |
Mar 05 2032 | patent expiry (for year 8) |
Mar 05 2034 | 2 years to revive unintentionally abandoned end. (for year 8) |
Mar 05 2035 | 12 years fee payment window open |
Sep 05 2035 | 6 months grace period start (w surcharge) |
Mar 05 2036 | patent expiry (for year 12) |
Mar 05 2038 | 2 years to revive unintentionally abandoned end. (for year 12) |